Alendronate improves fasting plasma glucose and insulin sensitivity and decreases insulin resistance in prediabetic osteopenic postmenopausal women: a randomized triple-blind clinical trial

KARIMI FARD, Maryam, AMINORROAYA, Ashraf, KACHUEI, Ali, SALAMAT, Mohammad Reza, HADI ALIJANVAND, Moluk, AMINORROAYA YAMINI, Sima, KARIMIFAR, Mansoor, FEIZI, Awat and AMINI, Massoud (2018). Alendronate improves fasting plasma glucose and insulin sensitivity and decreases insulin resistance in prediabetic osteopenic postmenopausal women: a randomized triple-blind clinical trial. Journal of Diabetes Investigation.

[img]
Preview
PDF
AminoroayaYamini-AlendronateImprovesFastingPlasma(AM).pdf - Accepted Version
Creative Commons Attribution.

Download (1MB) | Preview
Link to published version:: https://doi.org/10.1111/jdi.12944

Abstract

Aims Postmenopausal women receive bisphosphonates for osteoporosis treatment. The effect of these medications on developing diabetes mellitus (DM) in prediabetic patients is yet to be investigated. We aimed to determine the effect of alendronate on plasma glucose, insulin indices of postmenopausal women with prediabetes and osteopenia. Methods This triple‐blind randomized controlled clinical trial included 60 postmenopausal women, aged 45–60 years. All patients were vitamin D sufficient. They were randomly enrolled in intervention (70 mg/week alendronate for 12 week) and control (placebo tablet per week for 12 weeks) groups. The morning 8 hour fasting blood samples were collected at the baseline and follow–up visits to measure the fasting plasma glucose (FPG) (mg/dl), insulin and hemoglobin A1c (HbA1c). Plasma glucose and insulin concentration were measured 30, 60, and 120 minutes after glucose tolerance test. Matsuda index, homeostasis model assessment of insulin resistance (HOMA–IR), homeostasis model assessment of beta–cell function (HOMA–B) and the area under the curves (AUC) of glucose and insulin were calculated. Results Mean (SD) FPG (102.43 (1.46) mg/dl vs. 94.23)1.17) mg/dl, P=0.001), 120‐minutes insulin concentration (101.86)15.70) mU/l vs. 72.60 (11.36), P=0.026), HbA1c (5.60 (0.06) % vs. 5.40 (0.05)%, P=0.001), HOMA‐IR (3.57 (0.45) vs. 2.62 (0.24), P=0.021) and Matsuda index (7.7 (0.41) vs. 9.2 (0.4), P=0.001) significantly improved in the alendronate‐treated group. There was statistically significant more reductions in FPG (‐8.2 (8.63) mg/dl vs. ‐2.5 (14.26) mg/dl, P=0.002) and HbA1c (‐0.2 (0.23) % vs. ‐0.09 (0.26) %, P=0.015) were observed in alendronate‐treated group than placebo group during the study course, respectively. Conclusions Administration of 70 mg/week alendronate improves fasting plasma glucose, HbA1c and insulin indices in postmenopausal women.

Item Type: Article
Additional Information: ** From Crossref via Jisc Publications Router **Journal IDs: pissn 2040-1116
Uncontrolled Keywords: Internal Medicine, Endocrinology, Diabetes and Metabolism, General Medicine
Departments: Faculty of Science, Technology and Arts > Department of Engineering and Mathematics
Identification Number: https://doi.org/10.1111/jdi.12944
SWORD Depositor: Margaret Boot
Depositing User: Margaret Boot
Date Deposited: 12 Oct 2018 08:25
Last Modified: 06 Mar 2019 10:02
URI: http://shura.shu.ac.uk/id/eprint/22842

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year

View more statistics